medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended expanding the indication for pembrolizumab to include patients with advanced triple negative breast cancer (TNBC) and PD-L1 expression of at least 10%.
As per the decision, the PD-1 inhibitor should be given in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic TNBC that is chemotherapy naïve.
The positive opinion in this setting adds to the recommended use of pembrolizumab in patients with melanoma, non-small-cell lung cancer, classical Hodgkin lymphoma, urothelial cancer, head and neck squamous cell carcinoma, renal cell carcinoma, esophageal or gastroesophageal junction adenocarcinoma, and cancer of the colon or rectum.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group